LISTING OF THE CLAIMS

1-10. (Canceled)

- 11. (Currently amended) An inhalable medicament with an aerodynamic diameter of less than 20 µm, preferably less than 5 µm and greater than 0.3 µm, characterized in that it is produced by means of a process for the production of powders of inhalable medicaments by crystallization from a supersaturated fluid containing said inhalable medicament, the improved process comprising passing along a tubular reactor
 - (a) a segmented flow of a supersaturated fluid containing medicament comprised of discrete volumes; or
 - (b) a fluid mixture being separated by discrete volumes of a separating fluid which is substantially immiscible with the supersaturated fluid containing medicament,

and initiating crystallization by application of ultrasound wherein the inhalable medicament includes at least one of: montelukast; pramipexole; anticholinergics selected from the group consisting of: ipratropium bromide, oxitropium, tiotropium bromide or tiotroprium bromide-monohydrate; betasympathomimetics selected from the group consisting of: bambuterol, biolterol, carbuterol, formoterol, clenbuterol, fenoterol, hexoprenalin, procaterol, ibuterol, pirbuterol, tulobuterol, reproterol, salbutamol, salmeterol, sulfonterol, terbutalin, orciprenalin, 1-(2-fluoro-4-hydroxy-phenyl)-2-[4-(1benzimida-zolyl)-2-methyl-2-butylaminolethanol, erythro-5'-hydroxy-8'-(1-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-one, 1-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-tert.-butyl-amino)ethanol or 1-(4-ethoxycarbonylamin- o-3cyano-5-fluorophenyl)-2-(tert.-butylamino)ethanol; antiallergics selected from the group consisting of: disodiumchromeglicate, nedocromil or epinastin; and steroids selected from the group consisting of: flunisolide, dexamethasone-21-isonicotinate, seratrodast, mycophenolate mofetil, pranlukast, zileuton, butixocort, budesonide, deflazacort, fluticasone, proedrol, mometasin furoate, tipredan, beclometasone (or the 16,21dipropionate), beclomethasone, icomethasone enbutate, cyclometasone, cloprednol,

Application No. 10/685,254 Amendment dated October 8, 2007 Reply to Office Action mailed August 7, 2007

fluocortin butyl, halometasone, deflazacort, alclometasone, cyclometasone, alisactide, prednicarbate, hydrocortisone-butyrate propionate, tixocortol pivalate, alclometas zonedipropionate, lotrisone, canesten-HC, deprodone, fluticasone-propionate, methylprednisolone-aceponate, halopredone-acetate, mometasone, mometasone-furoate, hydrocortisone-aceponate, mometasone, ulobetasol-propionate, aminogluethimide, triamciolone, hydrocortisone, meprednisone, fluorometholone, dexamethasone, betamethasone, medrysone fluclorolone acetonide, fluocinolone acetonide, paramethasone-acetate, deprodon propionate, aristocort-diacetate, fluocinonide, mazipredone, difluprednate, betamethasone valerate, dexamethasoneisonicotinate, beclomethasone-dipropionate, fluocortoloncapronate, formocortal, triamcinolonhexacetonide, cloprednol, formebolone, clobetasone, endrisone, flunisolide, halcinonide, fluazacort, clobetasol, hydrocortisone-17-butyrate, diflorasone, fluocortin, amcinonide, netamethasone dipropionate, cortivazole, betamethasoneadamantoate, fluodexane, trilostan, budesonide, clobetasone, demetex, trimacinolone benetonide, 9.alpha.-chloro-6.alpha.-fluoro-11.beta. 17.alpha.-dihydroxy-16.-alpha.-methyl-3-oxo-1,4-androstadiene-17.beta.-ca- rboxy acid methylester-17-propionate or ST-126.

12. (New) The inhalable medicament according to claim 11, wherein the inhalable medicament has an aerodynamic diameter of less than 5 μ m and greater than 0.3 μ m.